Company profile: Jounce Therapeutics
1.1 - Company Overview
Company description
- Provider of first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors, driven by a proprietary product engine.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Jounce Therapeutics
Ikonisys
HQ: United States
Website
- Description: Provider of fully automated microscopy platforms and FISH-based diagnostic applications for early, accurate, non-invasive disease detection, including Ikoniscope20 for rare-cell detection and Ikoniscope20max with high-volume slide loading, plus oncoFISH solutions for bladder cancer (urine), HER2 status, cervical 3q26 gain in LSIL/ASCUS, and ALK gene rearrangements in non-small cell lung carcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikonisys company profile →
Neon Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies focused on neoantigen-targeted approaches to direct the immune system to recognize and attack cancer. Pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neon Therapeutics company profile →
Mustang Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for B-cell Non-Hodgkin Lymphoma, X-linked severe combined immunodeficiency (XSCID), and glioblastoma. Pipeline includes MB-106 (third-generation fully human antibody); MB-107/MB-207 (safety-modified lentiviral gene therapies for XSCID); MB-101 (IL13Rα2-targeted CAR T); MB-108 (oncolytic herpes simplex virus); and MB-109 (combining CAR T with oHSV to improve efficacy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mustang Bio company profile →
Immunis AI
HQ: United States
Website
- Description: Provider of non-invasive, blood-based Active Surveillance Tests for active surveillance and early detection of diseases, initially validated for prostate cancer with future applications in other urological cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunis AI company profile →
Iambic Therapeutics
HQ: United States
Website
- Description: Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iambic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Jounce Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Jounce Therapeutics
2.2 - Growth funds investing in similar companies to Jounce Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Jounce Therapeutics
4.2 - Public trading comparable groups for Jounce Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →